FDA Rules On Treatment INDs May Embolden More Patients To Ask For Trial Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency expects individual patient INDs to rise by 50 percent as a result of new regs.
You may also be interested in...
Orphan, Tropical Diseases Need Better Drug Development Guidance - Senate
A floor amendment to the Senate Agriculture/FDA appropriations bill would push FDA toward streamlining the development and regulation of drugs to treat rare diseases and neglected diseases in the developing world
Orphan, Tropical Diseases Need Better Drug Development Guidance - Senate
A floor amendment to the Senate Agriculture/FDA appropriations bill would push FDA toward streamlining the development and regulation of drugs to treat rare diseases and neglected diseases in the developing world
Expanded Access Program For Insmed’s Iplex Shows Power Of Patient Advocates At FDA
Lou Gehrig’s patients who appealed to the agency early will get access to drug; others enter a lottery system as part of a clinical trial.